Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
Total Valuation
Bicycle Therapeutics has a market cap or net worth of $462.71M. The enterprise value is $681.44M.
Market Cap$462.71M
Enterprise Value$681.44M
Share Statistics
Bicycle Therapeutics has 47.71M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding47.71M
Owned by Insiders23.88%
Owned by Instutions0.28%
Financial Efficiency
Bicycle Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -22.94%.
Return on Equity (ROE)-21.31%
Return on Assets (ROA)-17.67%
Return on Invested Capital (ROIC)-22.94%
Return on Capital Employed (ROCE)-23.59%
Revenue Per Employee$115,653.58
Profits Per Employee-$554,296.597
Employee Count305
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bicycle Therapeutics is -48.21. Bicycle Therapeutics’s PEG ratio is 0.51.
PE Ratio-48.21
PS Ratio231.02
PB Ratio10.28
Price to Fair Value10.28
Price to FCF-49.10
Price to Operating Cash Flow-49.47
PEG Ratio0.51
Income Statement
In the last 12 months, Bicycle Therapeutics had revenue of $35.27M and earned -$169.06M in profits. Earnings per share was -$2.88.
Revenue$35.27M
Gross Profit$29.78M
Operating Income-$233.08M
Pretax Income-$196.48M
Net Income-$169.06M
EBITDA-179.68M
Earnings Per Share (EPS)-2.88
Cash Flow
In the last 12 months, operating cash flow was -$164.72M and capital expenditures -$1.24M, giving a free cash flow of -$166.00M billion.
Operating Cash Flow-$164.72M
Free Cash Flow-$166.00M
Free Cash Flow per Share-$3.48
Dividends & Yields
Bicycle Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-2.04%
Earnings Yield-2.07%
Stock Price Statistics
Beta1.64
52-Week Price Change-67.60%
50-Day Moving Average10.02
200-Day Moving Average18.33
Relative Strength Index (RSI)34.56
Average Volume (3m)389.13K
Important Dates
Bicycle Therapeutics upcoming earnings date is May 1, 2025, Before Open.
Last Earnings DateFeb 25, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Bicycle Therapeutics as a current ratio of 13.81, with Debt / Equity ratio of <0.01
Current Ratio13.81
Quick Ratio13.81
Debt to Market Cap0.00
Net Debt to EBITDA5.31
Interest Coverage Ratio-121.31
Taxes
In the past 12 months, Bicycle Therapeutics has paid -$27.42M in taxes.
Income Tax-$27.42M
Effective Tax Rate2.74%
Enterprise Valuation
Bicycle Therapeutics EV to EBITDA ratio is -44.11, with an EV/FCF ratio of -43.83.
EV to Sales206.20
EV to EBITDA-44.11
EV to Free Cash Flow-43.83
EV to Operating Cash Flow-44.16
Balance Sheet
Bicycle Therapeutics has $879.52M in cash and marketable securities with $9.49M in debt, giving a net cash position of -$870.03M billion.
Cash & Marketable Securities$879.52M
Total Debt$9.49M
Net Cash-$870.03M
Net Cash Per Share-$18.24
Tangible Book Value Per Share$1.36
Margins
Gross margin is 100.00%, with operating margin of -594.96%, and net profit margin of -479.18%.
Gross Margin100.00%
Operating Margin-594.96%
Pretax Margin-492.69%
Net Profit Margin-479.18%
EBITDA Margin-467.45%
EBIT Margin-487.78%
Analyst Forecast
The average price target for Bicycle Therapeutics is $31.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$31.11
Price Target Upside364.33%
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast30.27%
EPS Growth Forecast44.12%